Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Sarcoma 1Plasma cell 1Lymphoid 1Dermatologic 1

Conditions

Lymphoma 15Lymphoma, Follicular 10Hodgkin Disease 8Lymphoma, Non-Hodgkin 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoma, Large B-Cell, Diffuse 6Breast Neoplasms 5Waldenstrom Macroglobulinemia 4Myelodysplastic Syndromes 4Mycosis Fungoides 4Multiple Myeloma 4Lymphoma, T-Cell, Cutaneous 4Leukemia 4Sezary Syndrome 3Neoplasms, Plasma Cell 3Lymphoma, Mantle-Cell 3Lymphoma, B-Cell 3Leukemia, Myeloid, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Sarcoma 2Neoplasms 2Melanoma 2Lymphoma, B-Cell, Marginal Zone 2Lung Neoplasms 2Liver Neoplasms 2Hematologic Neoplasms 2Head and Neck Neoplasms 2Glioblastoma 2

Interventions

pembrolizumab 3temsirolimus 1spartalizumab 1poly ICLC 1patritumab 1durvalumab 1atezolizumab 1advexin 1Tetanus Toxoid 1Sunitinib 1Rifampin 1Radiation 1Nivolumab 1Midazolam 1Ketoconazole 1Ipilimumab 1Interleukin-15 1Brentuximab Vedotin 1Blood Specimen Collection 1Axitinib 13-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione 12,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid 11-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino(2,3-b)pyrazin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × Blood Specimen Collection × Lymphoid × Clear all
NCT01916135 2020-04-27

PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
11 enrolled
DermatologicLymphoidPlasma cellSarcoma

Carcinoma, Lymphoma, Melanoma, Sarcoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡